Category: Press Releases

Posted on

EMGA ได้บรรลุข้อตกลงเงินกู้ไม่ด้อยค่าจำนวน 30.0 ล้าน USD สำหรับ Citizens Development Business Finance PLC ในศรีลังกา

ลอนดอน, Jan. 12, 2024 (GLOBE NEWSWIRE) — Emerging Markets Global Advisory LLP (EMGA) ซึ่งเป็นธนาคารเพื่อการลงทุนที่เชี่ยวชาญด้านตลาดเกิดใหม่ ได้บรรลุข้อตกลงเงินกูไม่กู้ไม่ด้อยค่าจำนวน 30.0 ล้าน USD สำหรับ Citizens Development Business Finance PLC (CDB) ซึ่งตั้งอยู่ในศรีลังกา EMGA เป็นผู้ริเริ่ม จัดทำ และดำเนินการเจรจาต่อรองในข้อตกลงทางการเงินนี้ โดยได้รับความช่วยเหลือทางการเงินจาก U.S. International Development Finance Corporation (DFC)

Sajeev Chakkalakal ซึ่งเป็นหัวหน้าวาณิชธรกิจของ EMGA กล่าวว่า “แม้จะพบกับอุปสรรคต่าง ๆ มากมาย แต่เรามีความยินดีที่สามารถมอบนวัตกรรมโซลูชันด้านเงินทุนให้แก่ CDB ได้อีกครั้ง เราเชื่อว่านี่คือหมุดหมายสำคัญ โดยเป็นการบรรลุข้อตกลงทางการเงินจากภายนอกที่ให้แก่สถาบันการเงินที่มิใช่ธนาคารพาณิชย์ของศรีลังกาครั้งแรกในรอบหลายปี และยังทำให้ CDB สามารถสนับสนุนธุรกิจ SME ต่อไป รวมถึงองค์กรที่มีสตรีเป็นเจ้าของ และภาคส่วนพลังงานหมุนเวียนของประเทศอีกด้วย”

Jeremy Dobson ซึ่งเป็นประธานเจ้าหน้าที่ฝ่ายปฏิบัติการของ EMGA กล่าวว่า “สถานะทางการเงินที่มั่นคงของ CDB ทำให้ EMGA สามารถฝ่าแรงต้านด้านเศรษฐศาสตร์มหัพภาคในศรีลังกาจนบรรลุข้อตกลงด้านเงินทุนครั้งนี้ ความสำเร็จครั้งนี้ไม่เพียงแต่เน้นย้ำถึงความเชี่ยวชาญของ EMGA ในการดำเนินการในภูมิทัศน์ภาคการเงินที่ซับซ้อนเท่านั้น แต่ยังแสดงให้เห็นถึงความสำเร็จในการร่วมมือระหว่าง EMGA, CDB และ DFC เพื่อเป็นแบบอย่างเชิงบวกให้แก่สถาบันทางการเงินชั้นนำของศรีลังกาในการบรรลุข้อตกลงด้านเงินทุนจากภายนอกในสภาพเศรษฐกิจอันยากลำบาก”

Maryam Khosharay รักษาการแทนรองประธานสำนักงานเครดิตเพื่อการพัฒนาของ DFC กล่าวว่า “เรามีความยินดีเป็นอย่างยิ่งที่สามารถบรรลุข้อตกลงของ DFC ในการสนับสนุนการลงทุนในศรีลังกาต่อไป โดยเฉพาะความก้าวหน้าด้านการเงินสำหรับสตรีและสินทรัพย์เพื่อสิ่งแวดล้อมในช่วงเวลาที่ประสบอุปสรรคทางเศรษฐกิจและราคาพลังงานสูง”

Roshan Abeygoonewardena ซึ่งเป็นผู้อำนวยการฝ่ายการเงินธุรกิจของ CDB กล่าวถึงธุรกรรมครั้งนี้โดยให้ความเห็นว่า CDB ได้ช่วยสร้างเสริมความมั่นคงให้ฐานพีระมิดอย่างต่อเนื่องในฐานะจริยธรรมสำคัญของวาระด้านความยั่งยืน “สำหรับนักลงทุนสตรีแล้ว ส่วนจุลภาคและ SME คือส่วนที่วงล้อเศรษฐกิจหมุนเป็นพิเศษ การให้ความสำคัญกับการส่งเสริมสตรีในโมเดลธุรกิจของเราด้วยการเข้าถึงการเงิน ซึ่งจะช่วยกระตุ้นความเป็นอิสระทางการเงินและการยอมรับความแตกต่าง จะเป็นกลไกสำคัญในการกระตุ้นการพัฒนาและวาระทางเศรษฐกิจของศรีลังกา”

Emerging Markets Global Advisory LLP (EMGA) ซึ่งตั้งอยู่ในลอนดอนและนิวยอร์กได้ช่วยสถาบันและองค์กรทางการเงินต่างๆ ในการสรรหาเงินทุนจากการกู้หรือจากหุ้น ทีมงานนานาชาติของ EMGA มีประสบการณ์รวมกันหลายทศวรรษที่จำเป็นต่อการทำธุรกรรมให้สำเร็จในประเทศตลาดเกิดใหม่ส่วนใหญ่ รวมถึงศรีลังกา EMGA ขยายตัวไปทั่วโลกอย่างไม่หยุดยั้ง และยกสถานะเป็นธนาคารเพื่อการลงทุนชั้นนำที่มุ่งเน้นในตลาดเกิดใหม่

Citizens Development Business Finance PLC (CDB) เป็นหนึ่งในห้าสถาบันการเงินที่มิใช่ธนาคารพาณิชย์ที่ใหญ่ที่สุดในศรีลังกา และเป็นหนึ่งในสถาบันการเงินที่ทันสมัยที่สุดในประเทศ โดยมีความมุ่งมั่นอย่างแรงกล้าต่อความยั่งยืน บรรษัทภิบาลอันเป็นแบบอย่าง ความรับผิดชอบ และความโปร่งใส โด่งดังด้านการปฏิวัติอุตสาหกรรมบริการทางการเงินด้วยนวัตกรรมทางเทคโนโลยีอันกว้างขวางและโซลูชันทางการเงินที่ล้ำสมัย

U.S. International Development Finance Corporation (DFC) เป็นสถาบันพัฒนาทางการเงินของรัฐบาลสหรัฐอเมริกา DFC ร่วมมือกับภาคเอกชนเพื่อสนับสนุนโซลูชันทางการเงินให้แค่ประเทศกำลังพัฒนาที่ประสบปัญหาทางการเงินอย่างร้ายแรงที่สุดในปัจจุบัน เราลงทุนในหลายภาคส่วน รวมถึงพลังงาน การดูแลสุขภาพ โครงสร้างพื้นฐาน เกษตรกรรม และธุรกิจขนาดเล็กและบริการทางการเงิน DFC ลงทุนโดยยึดถือมาตรฐานที่สูงและเคารพต่อสิ่งแวดล้อม สิทธิมนุษยชน และสิทธิแรงงาน

รายละเอียดการติดต่อ
info@emergingmarketsglobaladvisory.com

GlobeNewswire Distribution ID 1000908404

Posted on

CNH and HD Hyundai announce joint innovation program for the construction sector at CES

CNH and HD Hyundai executives at CES

From left to right: Kisun Chung, Vice Chairman and CEO of HD Hyundai; Stefano Pampalone President, Construction at CNH; Young Cheul Cho, President and CEO of HD Hyundai XiteSolution; and Scott W. Wine, CEO at CNH

CNH and HD Hyundai announce joint innovation program for the construction sector at CES

Las Vegas, January 11, 2024

CNH and HD Hyundai announced a new development in their longstanding collaboration at the CES Show in Las Vegas, USA today.

Stefano Pampalone, President Construction at CNH and Young-Cheul Cho, President and CEO of HD Hyundai XiteSolution (HDX), the controlling company of HD Hyundai Construction Equipment and HD Hyundai Infracore, signed a Memorandum of Understanding to establish a joint research center in the United States.

CNH and HDX possess an extensive background in construction with unique areas of expertise and strengths. This strategic collaboration aims to expand upon their existing capabilities to accelerate the development and investment in innovative technologies for customers in the construction industry.

The CE Innovation Lab will be dedicated to exploring innovation opportunities in the construction sector. The team, comprised of both CNH and HDX construction specialists, will study emerging technology trends, map new and evolving customer needs and identify prospects for portfolio enhancements and further growth. Their work together will advance the development and widespread adoption of new technologies, such as automation and Artificial Intelligence.

Further to this, the parties will mutually benefit from each other’s distinctive technological capabilities. HDX will supply CNH with their patented AAVM+ (Advanced Around View Monitoring Plus) 360-degree camera and radar system delivering enhanced safety. CNH will supply HDX with Global Navigation Satellite System technologies through its Hemisphere brand.

In the future, CNH and HDX anticipate expanding their collaboration within the research center to encompass the co-development of new technologies and co-investment in innovative start-ups via their CNH Ventures and HD Hyundai investment arms.

“We are excited to expand our collaboration with HDX. This joint effort will strengthen our commitment to growing CNH’s construction business and position both our companies as tech authorities in the industry,” said Stefano Pampalone – President, Construction at CNH.

“It is highly encouraging that our partnership has extended beyond our product collaboration to include future technologies, a crucial factor to remain at the forefront of the construction equipment market. We look forward to working together even more closely to lead the way in the market.” said Young-Cheul Cho, President and CEO of HDX and Hyundai Infracore Co., Ltd.

CNH Industrial (NYSE: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland supply 360° agriculture applications from machines to implements and the digital technologies that enhance them; and CASE and New Holland Construction Equipment deliver a full lineup of construction products that make the industry more productive. The Company’s regionally focused Brands include: STEYR, for agricultural tractors; Raven, a leader in digital agriculture, precision technology and the development of autonomous systems; Hemisphere, a leading designer and manufacturer of high-precision satellite-based positioning, and heading technologies; Flexi-Coil, specializing in tillage and seeding systems; Miller, manufacturing application equipment; Kongskilde, providing tillage, seeding and hay & forage implements; and Eurocomach, producing a wide range of mini and midi excavators for the construction sector, including electric solutions.

Across a history spanning over two centuries, CNH has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH’s 40,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world.

For more information and the latest financial and sustainability reports visit: cnh.com

For news from CNH and its Brands visit: media.cnhindustrial.com

About HD Hyundai XiteSolutionHD Hyundai XiteSolution is the intermediate holding company in the construction equipment sector of HD Hyundai, one of South Korea’s largest heavy industries conglomerates engaged in shipbuilding, heavy equipment, and energy business.

Founded in 2021 and headquartered in South Korea, HD Hyundai XiteSolution aims to create synergy between its subsidiaries, HD Hyundai Construction Equipment (HCE) and HD Hyundai Infracore (HDI), major machine manufacturing companies with a leading position in construction equipment, engines, attachments, utility equipment and more. The two subsidiaries operate under its respective brands, Hyundai and DEVELON. While HCE and HDI each operate independently, HD Hyundai XiteSolution seeks to maximize the synergy between the two in R&D, purchasing, sales and international business.

Alongside providing optimized solutions that propel synergy, HD Hyundai XiteSolution also targets to shape and solidify its own industrial vehicle and hydraulic component business by achieving ten trillion won in sales by 2025, becoming a global top five company in the field of construction machinery, and realizing its vision to create a blueprint for the future of the construction equipment industry in Korea.

To learn more, visit: https://www.hd-xitesolution.com/?locale=en

Contacts:

CNH Media Relations                     
Email: mediarelations@cnhind.com

HDX Media Relations
Billie Lee
Email: billie.lee@hd.com

Forward-looking statements

All statements other than statements of historical fact contained in this press release, including competitive strengths; business strategy; future financial position or operating results; budgets; projections with respect to revenue, income, earnings (or loss) per share, capital expenditures, dividends, liquidity, capital structure or other financial items; costs; and plans and objectives of management regarding operations and products, are forward-looking statements. Forward looking statements also include statements regarding the future performance of CNH Industrial and its subsidiaries on a standalone basis. These statements may include terminology such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “outlook”, “continue”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “prospects”, “plan”, or similar terminology. Forward-looking statements are not guarantees of future performance. Rather, they are based on current views and assumptions and involve known and unknown risks, uncertainties and other factors, many of which are outside our control and are difficult to predict. If any of these risks and uncertainties materialize (or they occur with a degree of severity that the Company is unable to predict) or other assumptions underlying any of the forward-looking statements prove to be incorrect, including any assumptions regarding strategic plans, the actual results or developments may differ materially from any future results or developments expressed or implied by the forward-looking statements. Factors, risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements include, among others: economic conditions in each of our markets, including the significant uncertainty caused by the war in the Ukraine; the duration and economic, operational and financial impacts of the global COVID-19 pandemic; production and supply chain disruptions, including industry capacity constraints, material availability, and global logistics delays and constraints; the many interrelated factors that affect consumer confidence and worldwide demand for capital goods and capital goods-related products; changes in government policies regarding banking, monetary and fiscal policy; legislation, particularly pertaining to capital goods-related issues such as agriculture, the environment, debt relief and subsidy program policies, trade and commerce and infrastructure development; government policies on international trade and investment, including sanctions, import quotas, capital controls and tariffs; volatility in international trade caused by the imposition of tariffs, sanctions, embargoes, and trade wars; actions of competitors in the various industries in which we compete; development and use of new technologies and technological difficulties; the interpretation of, or adoption of new, compliance requirements with respect to engine emissions, safety or other aspects of our products; labor relations; interest rates and currency exchange rates; inflation and deflation; energy prices; prices for agricultural commodities and material price increases; housing starts and other construction activity; our ability to obtain financing or to refinance existing debt; price pressure on new and used equipment; the resolution of pending litigation and investigations on a wide range of topics, including dealer and supplier litigation, intellectual property rights disputes, product warranty and defective product claims, and emissions and/or fuel economy regulatory and contractual issues; security breaches, cybersecurity attacks, technology failures, and other disruptions to the information technology infrastructure of CNH Industrial and its suppliers and dealers; security breaches with respect to our products; our pension plans and other post-employment obligations; political and civil unrest; volatility and deterioration of capital and financial markets, including pandemics, terrorist attacks in Europe and elsewhere; our ability to realize the anticipated benefits from our business initiatives as part of our strategic plan; our failure to realize, or a delay in realizing, all of the anticipated benefits of our acquisitions, joint ventures, strategic alliances or divestitures and other similar risks and uncertainties, and our success in managing the risks involved in the foregoing.

Forward-looking statements are based upon assumptions relating to the factors described in this press release, which are sometimes based upon estimates and data received from third parties. Such estimates and data are often revised. Actual results may differ materially from the forward- looking statements as a result of a number of risks and uncertainties, many of which are outside CNH Industrial’s control. CNH Industrial expressly disclaims any intention or obligation to provide, update or revise any forward-looking statements in this announcement to reflect any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. Further information concerning CNH Industrial, including factors that potentially could materially affect CNH Industrial’s financial results, is included in CNH Industrial’s reports and filings with the U.S. Securities and Exchange Commission (“SEC”).

All future written and oral forward-looking statements by CNH Industrial or persons acting on the behalf of CNH Industrial are expressly qualified in their entirety by the cautionary statements contained herein or referred to above.

Attachments

GlobeNewswire Distribution ID 1000908356

Posted on

Boehringer expands production site in Greece for new medicine

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications. Main disease areas include cardio-renal-metabolic (CRM) diseases, mental health, pulmonary fibrosis, systemic sclerosis, and chronic liver disease, some of them in the late-stage development of the company’s strong innovation pipeline. The expansion will create 110 additional jobs and boost medicine exports from Greece, particularly of Jardiance®, a medication used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease, to the US market.

Greek Prime Minister Kyriakos Mitsotakis attended the groundbreaking ceremony at the Koropi site today, alongside the Minister of State, the Minister of Health and the Minister of Development. He said: “I am delighted to once again visit this plant which, as we have heard, produces some of the most innovative antidiabetic medicines, and to see the excellent organization as well as the high level of expertise and professionalism. I am also very pleased with the progress that the company has made; with the 700 skilled employees whose number will increase by more than 100 when this investment is completed; and, of course, with this important shift towards innovation. I want to thank the company for its continuous trust in Greece. But first and foremost, the company trusts you, the employees, not just the government or the wider environment. All together you constitute a team, building a better tomorrow, a structure with very strong foundations and that is what we are celebrating here today. You showcase the great importance we associate with the creation of value through innovation. It is a strategic goal that we as a state also embrace: to make our country a reference point for the pharmaceutical industry.”

Putting innovative production technologies in place to support successful Research & Development (R&D) is a key investment driver at Boehringer. In 2022, the company’s global expenditure in Human Pharma R&D amounted to 4.6 billion EUR. 25% of Human Pharma net sales are reinvested to advance science and cutting-edge research to find new therapies and treatments for patients who are waiting for new solutions in areas of high unmet patient needs. More than half of its 53,000 workforce and over 60% of R&D budgets are invested in Europe.

“We have been present in Greece since 1996, and have gradually expanded our operations in the country,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors at Boehringer Ingelheim. “This expansion investment will bring some of our most innovative therapies to an increasing number of patients globally.”

Boehringer started the production facility in Koropi in 1975. In 2020, the company announced multi-year investments to expand the site and its production capacity. The Koropi plant is the only industrial facility of a multinational pharmaceutical company in Greece producing innovative medicines.

Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com.

Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Click here to see the press release on the company website

GlobeNewswire Distribution ID 1000908358

Posted on

General Fusion Confirms Liquid Wall Compression Technology for Commercial Magnetized Target Fusion in New Scientific Publication

A liquid compression system prototype at General Fusion’s Canadian labs

In three years, General Fusion commissioned a prototype of its liquid compression system and completed over 1,000 shots, validating the compression technology for commercial Magnetized Target Fusion.

RICHMOND, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) — General Fusion has published new, peer-reviewed scientific results that validate the company has achieved the smooth, rapid, and symmetric compression of a liquid cavity that is key to the design of a commercial Magnetized Target Fusion power plant. The results, published in one of the foremost scientific journals in fusion, Fusion Engineering and Design, validate the performance of General Fusion’s proprietary liquid compression technology for Magnetized Target Fusion and are scalable to a commercial machine.

General Fusion’s Magnetized Target Fusion technology uses mechanical compression of a plasma to achieve fusion conditions. High-speed drivers rapidly power a precisely shaped, symmetrical collapse of a liquid metal cavity that envelopes the plasma. In three years, General Fusion commissioned a prototype of its liquid compression system and completed over 1,000 shots, validating the compression technology. In addition, this scale model of General Fusion’s commercial compression system verified the company’s open-source computational fluid dynamics simulation. The paper confirms General Fusion’s concept for the compression system of a commercial machine.

“General Fusion has proven success scaling individual technologies, creating the pathway to integrate, deploy, and commercialize practical fusion energy,” said Greg Twinney, CEO, General Fusion. “The publication of these results demonstrates General Fusion has the science and engineering capabilities to progress the design of our proprietary liquid compression system to commercialization.”

General Fusion’s approach to compressing plasma to create fusion energy is unique. Its Magnetized Target Fusion technology is designed to address the barriers to commercialization that other fusion technologies still face. The game-changer is the proprietary liquid metal liner in the fusion vessel that is mechanically compressed by high-powered pistons. This allows General Fusion to create fusion conditions in short pulses, rather than creating a sustained reaction, while protecting the machine’s vessel, extracting heat, and re-breeding fuel.

Today at its Canadian labs, General Fusion is building a ground-breaking Magnetized Target Fusion demonstration called Lawson Machine 26 (LM26). Designed to reach fusion conditions of over 100 million degrees Celsius by 2025 and progress towards scientific breakeven equivalent by 2026, LM26 fast-tracks General Fusion’s technical progress to provide commercial fusion energy to the grid by the early to mid-2030s.

About General Fusion
General Fusion is pursuing a fast and practical approach to commercial fusion energy and is headquartered in Richmond, Canada. The company was established in 2002 and is funded by a global syndicate of leading energy venture capital firms, industry leaders, and technology pioneers. Learn more at generalfusion.com.

General Fusion Media Relations
media@generalfusion.com
+1-866-904-0995

Follow General Fusion
twitter.com/generalfusion
instagram.com/generalfusion
linkedin.com/company/general-fusion
facebook.com/generalfusion
youtube.com/c/GeneralFusionInc

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ff44db55-0250-4800-976e-f631f113283d

GlobeNewswire Distribution ID 9016259

Posted on

New study confirms Smith+Nephew’s REGENETEN™ Bioinductive Implant reduces full-thickness rotator cuff re-tear rates¹ by 68%

REGENETEN Patch 2024

Smith+Nephew’s REGENETEN Bioinductive Implant

First published randomized controlled trial for market-leading implant demonstrates impressive outcomes for rotator cuff tears               

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces standout results for its REGENETEN Bioinductive Implant from a recently completed randomized controlled trial (RCT). Published online in Arthroscopy in December, the report concluded that at one-year, medium and large full-thickness rotator cuff tears repaired and augmented with the REGENETEN Bioinductive Implant had better tendon healing compared to the standard of care,1 as evidenced by:

  • A significantly lower re-tear rate (8.3 vs 25.8%; p=0.01)
  • A three times lower risk of re-tear (RR=0.32; 95% CI:0.13–0.83)
  • No difference in the number of serious or minor complications

The blinded, multi-centre RCT compared the healing rate of full-thickness rotator cuff tears repaired with and without augmentation with the REGENETEN Bioinductive Implant. In total, 124 patients with reparable medium and large (1–4cm) full-thickness posterosuperior rotator cuff tears were randomized to receive either an arthroscopic transosseous equivalent double-row rotator cuff repair or the same repair augmented with the REGENETEN Bioinductive Implant.

Dr. Miguel Ruiz Ibán, Head of the Shoulder and Elbow Unit at Hospital Universitario Ramón y Cajal in Madrid, Spain, and Principal Investigator for the study commented on the results, “Rotator cuff repair is traditionally associated with re-tear rates in excess of 20%, presenting a challenge for surgeons and patients alike. This RCT demonstrates that the REGENETEN Bioinductive Implant substantially and significantly reduced this risk. With no increase in complications seen in our study, these findings support the use of the implant to reduce re-tear rates in the population studied.”

With more than 100,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for more than 1 million2 people having surgery for a rotator cuff tear each year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of rotator cuff tear progression.1,3-8

Smith+Nephew’s REGENETEN Bioinductive Implant

“Smith+Nephew is committed to proving the value of our technology through support for clinical evidence generation,” said Christie Van Geffen, SVP Sports Medicine Global Marketing at Smith+Nephew. “We are pleased and excited by the opportunity presented by this evidence to drive adoption of, and access to, the REGENETEN Bioinductive Implant. Our goal is to help surgeons improve the care of many more patients with rotator cuff injuries.”

The REGENETEN Bioinductive Implant is part of Smith+Nephew’s comprehensive Advanced Healing Solutions portfolio – redefining biological healing in rotator cuff repair.

To learn more about the REGENETEN Bioinductive Implant, please click here.

Media Enquiries

David Snyder
Smith+Nephew
+1 978-749-1440
david.snyder@smith-nephew.com

References

  1. Ruiz Ibán MA, Navlet MG, Marco SM, et al.  Augmentation of a transosseous equivalent repair in posterosuperior non-acute rotator cuff tears with a bioinductive collagen implant decreases the re-tear rate at one year. A randomised controlled trial. Arthroscopy. Published online 12/27/2023.
  2. iData Research. Rotator cuff repair and reconstruction market size, share and trends analysis (2023). Available at: https://idataresearch.com/product/rotator-cuff-repair-reconstruction-market-size-share-and-trends-analysis-global-2023-2029-medsuite-includes-grafts-allografts-xenograft-synthetic-and-1-more/#. Accessed December 19, 2023.
  3. Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles, Ligaments Tendons J. 2016;6(1):16-25.
  4. Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251.
  5. Van Kampen C, Arnoczky S, Parks P, et al. Tissue-engineered augmentation of a rotator cuff tendon using a reconstituted collagen scaffold: a histological evaluation in sheep. Muscles Ligaments Tendons J. 2013;3(3):229-235.
  6. Arnoczky SP, Bishai SK, Schofield B, et al. Histologic Evaluation of Biopsy Specimens Obtained After Rotator Cuff Repair Augmented With a Highly Porous Collagen Implant. Arthroscopy. 2017;33(2):278-283
  7. Bokor DJ, Sonnabend DH, Deady L, et al. Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments Tendons J. 2019;9(3):338-347.
  8. McElvany MD, McGoldrick E, Gee AO, Neradilek MB, Matsen FA, 3rd. Rotator cuff repair: published evidence on factors associated with repair integrity and clinical outcome. Am J Sports Med. 2015;43(2):491-500.

About Smith+Nephew
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 19,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of Covid, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of Covid; economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers (including, without limitation, as a result of Covid); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of Covid); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F,  which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

Smith+Nephew’s REGENETEN Bioinductive Implant

Attachment

GlobeNewswire Distribution ID 1000908200

Posted on

Quantexa Partners with the Anti-Human Trafficking Intelligence Initiative (ATII) to Intensify the Fight Against Human Trafficking

Quantexa to provide category-leading AI-enabled technology, training, and industry expertise to ATII to improve how data is used in the identification and investigation of human trafficking

NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) — Today, Quantexa, a global leader in Decision Intelligence (DI) solutions for the public and private sectors, announced its official corporate sponsorship and Advisory Council membership of the Anti-Human Trafficking Intelligence Initiative (ATII), to mark National Human Trafficking Awareness Day. The ATII is a US-based nonprofit organization whose mission is to fight human trafficking and child exploitation by providing data to advance the prevention, detection, investigation, and reporting mechanisms required to identify potential traffickers and criminal organizations. The International Labor Organization estimates that 50 million1 people are victims of human trafficking globally, with human trafficking operating as a $150 billion2 industry around the world.

Quantexa will provide groundbreaking Decision Intelligence technology, alongside its industry-leading expertise in AI-driven financial crime prevention and detection through training and joint industry engagement. Together, Quantexa and ATII will make pioneering global human trafficking risk data available to more organizations to transform anti-human trafficking efforts and joint initiatives between the private and public sectors.

The Quantexa Decision Intelligence Platform enables organizations to automate data ingestion and matching at unmatched scale and apply graph analytics to visually identify often hard-to-detect activity related to financial crime. Providing access to a wider set of data points specific to human trafficking will enable investigators to take a more robust approach to anti-human trafficking measures. This data, overlaid with persona-based typologies and red flag identification protocols will accelerate the ID of potential human trafficking involvement more quickly, efficiently, and accurately.

“Partnering with Quantexa grants us access to innovative AI technology that will take our mission to fight human trafficking to the next level, transforming our existing processes and providing our partners with improved data to inform investigations faster and more efficiently,” said Aaron Kahler, Founder and CEO of ATII. “Working with Quantexa will put ATII’s data in the hands of more organizations across the public and private sectors, to help detect and eliminate more instances of human trafficking as we work together towards ensuring this type of data is routinely available to investigators.”

“We’re proud to partner with the Anti-Human Trafficking Intelligence Initiative to support the valuable work that the organization is doing to stop human trafficking,” said Clark Frogley, North American Head of Financial Crime Solutions at Quantexa. “Human trafficking is often enabled by illegal financial activity and Quantexa’s deep experience helping organizations to monitor, detect, and investigate financial crimes makes us the ideal partner to support ATII’s mission. This partnership will aid organizations to reinforce their ESG and anti-money laundering (AML) efforts which are critical to stopping human trafficking.”

For more information on global challenges and solutions related to human trafficking, please listen to this podcast featuring Chris Bagnall, Director of Financial Crimes Solutions at Quantexa, Chris Kemp, Director of Enterprise Operations at the ATII and Karim Rajwani, ATII Advisory Council Chairman on Moody’s Talks.

About Quantexa
Quantexa is a global data and analytics software company pioneering Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. Using the latest advancements in big data and AI, Quantexa’s Decision Intelligence platform uncovers hidden risk and new opportunities by providing a contextual, connected view of internal and external data in a single place. It solves major challenges across data management, KYC, customer intelligence, financial crime, risk, fraud, and security, throughout the customer lifecycle.

The Quantexa Decision Intelligence Platform enhances operational performance with over 90% more accuracy and 60 times faster analytical model resolution than traditional approaches. Founded in 2016, Quantexa now has more than 675 employees and thousands of users working with billions of transactions and data points across the world. The company has offices in London, Dublin, Brussels, Malaga, UAE, New York, Boston, Toronto, Sydney, Melbourne, and Tokyo.

For more information, please visit www.quantexa.com or follow us on LinkedIn.

Media Enquiries 
C: Emma Hedges, Executive Vice President, Fight or Flight
E: Quantexa@fightorflight.com

C: Adam Jaffe, SVP of Corporate Marketing
T: +1 609 502 6889
E: adamjaffe@quantexa.com
– or –
RapidResponse@quantexa.com

________________________________

1 International Labour Organization (ILO), Walk Free and International Organization for Migration (IOM), “Global Estimates of Modern Slavery: Forced Labour and Forced Marriage,” 2022

2 International Labour Office (ILO), “Profits and Poverty: The Economics of Forced Labour,” 2014

GlobeNewswire Distribution ID 1000908209

Posted on

Quantexa Partners with the Anti-Human Trafficking Intelligence Initiative (ATII) to Intensify the Fight Against Human Trafficking

Quantexa to provide category-leading AI-enabled technology, training, and industry expertise to ATII to improve how data is used in the identification and investigation of human trafficking

NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) — Today, Quantexa, a global leader in Decision Intelligence (DI) solutions for the public and private sectors, announced its official corporate sponsorship and Advisory Council membership of the Anti-Human Trafficking Intelligence Initiative (ATII), to mark National Human Trafficking Awareness Day. The ATII is a US-based nonprofit organization whose mission is to fight human trafficking and child exploitation by providing data to advance the prevention, detection, investigation, and reporting mechanisms required to identify potential traffickers and criminal organizations. The International Labor Organization estimates that 50 million1 people are victims of human trafficking globally, with human trafficking operating as a $150 billion2 industry around the world.

Quantexa will provide groundbreaking Decision Intelligence technology, alongside its industry-leading expertise in AI-driven financial crime prevention and detection through training and joint industry engagement. Together, Quantexa and ATII will make pioneering global human trafficking risk data available to more organizations to transform anti-human trafficking efforts and joint initiatives between the private and public sectors.

The Quantexa Decision Intelligence Platform enables organizations to automate data ingestion and matching at unmatched scale and apply graph analytics to visually identify often hard-to-detect activity related to financial crime. Providing access to a wider set of data points specific to human trafficking will enable investigators to take a more robust approach to anti-human trafficking measures. This data, overlaid with persona-based typologies and red flag identification protocols will accelerate the ID of potential human trafficking involvement more quickly, efficiently, and accurately.

“Partnering with Quantexa grants us access to innovative AI technology that will take our mission to fight human trafficking to the next level, transforming our existing processes and providing our partners with improved data to inform investigations faster and more efficiently,” said Aaron Kahler, Founder and CEO of ATII. “Working with Quantexa will put ATII’s data in the hands of more organizations across the public and private sectors, to help detect and eliminate more instances of human trafficking as we work together towards ensuring this type of data is routinely available to investigators.”

“We’re proud to partner with the Anti-Human Trafficking Intelligence Initiative to support the valuable work that the organization is doing to stop human trafficking,” said Clark Frogley, North American Head of Financial Crime Solutions at Quantexa. “Human trafficking is often enabled by illegal financial activity and Quantexa’s deep experience helping organizations to monitor, detect, and investigate financial crimes makes us the ideal partner to support ATII’s mission. This partnership will aid organizations to reinforce their ESG and anti-money laundering (AML) efforts which are critical to stopping human trafficking.”

For more information on global challenges and solutions related to human trafficking, please listen to this podcast featuring Chris Bagnall, Director of Financial Crimes Solutions at Quantexa, Chris Kemp, Director of Enterprise Operations at the ATII and Karim Rajwani, ATII Advisory Council Chairman on Moody’s Talks.

About Quantexa
Quantexa is a global data and analytics software company pioneering Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. Using the latest advancements in big data and AI, Quantexa’s Decision Intelligence platform uncovers hidden risk and new opportunities by providing a contextual, connected view of internal and external data in a single place. It solves major challenges across data management, KYC, customer intelligence, financial crime, risk, fraud, and security, throughout the customer lifecycle.

The Quantexa Decision Intelligence Platform enhances operational performance with over 90% more accuracy and 60 times faster analytical model resolution than traditional approaches. Founded in 2016, Quantexa now has more than 675 employees and thousands of users working with billions of transactions and data points across the world. The company has offices in London, Dublin, Brussels, Malaga, UAE, New York, Boston, Toronto, Sydney, Melbourne, and Tokyo.

For more information, please visit www.quantexa.com or follow us on LinkedIn.

Media Enquiries 
C: Emma Hedges, Executive Vice President, Fight or Flight
E: Quantexa@fightorflight.com

C: Adam Jaffe, SVP of Corporate Marketing
T: +1 609 502 6889
E: adamjaffe@quantexa.com
– or –
RapidResponse@quantexa.com

________________________________

1 International Labour Organization (ILO), Walk Free and International Organization for Migration (IOM), “Global Estimates of Modern Slavery: Forced Labour and Forced Marriage,” 2022

2 International Labour Office (ILO), “Profits and Poverty: The Economics of Forced Labour,” 2014

GlobeNewswire Distribution ID 1000908209